Oxford Gene Technology is a leading provider of genetics research solutions.
Oxford Gene Technology – genetics solutions
Oxford Gene Technology (OGT) proposes SureSeq Solid Tumour Panel, a fully validated tool for an accurate determination of allele frequency. Comprehensive variant detection is performed by targeting every codon of every exon in 60 key genes. Thus, the 60-gene NGS SureSeq Solid Tumour Panel allows discovery of novel variants in a wide range of solid tumours.
CytoSure Molecular Arrays are designed to accurately identify small intragenic copy number variations (CNVs) in genes associated with various disorders. CytoSure Embryo Screen Array enables the reliable screening of up to 14 embryos for chromosome number abnormalities. CytoSure Embryo Screen Array uses long oligo array comparative genomic hybridisation (aCGH) for superior aneuploidy and copy number detection. Furthermore, the CytoSure Aneuploidy array has been developed to allow the detection of aneuploidy for research into miscarriage samples, with a fast turnaround time (delivering results in 2 or 3 days). Oxford Gene Technology also offers the CytoSure Medical Research Exome Array, a highly targeted exon-focused array able to detect medically relevant microdeletions and microduplications. Using highly targeted optimized probes, this Exome Array detect single or multiple exonic CNVs on 4600 hand-curated research-validated genes. CytoSure Medical Research Exome Array makes an ideal complement to an exome sequencing approach in order to provide a comprehensive mutation spectrum analysis in rare disease.
Cytocell FISH Probes are very usefull for the detection of gene rearrangements related to inherited genetic disease and cancer. OGT recently acquired Cytocell Ltd. to provide researchers with a high-quality range of FISH probes covering various genetic disorders. OGT ‘s CytoSure, Cytocell, SureSeq and Genefficiency microarrays, as well as FISH and next generation sequencing products and services deliver high-quality genetic analysis, thus enabling accurate identification of the causative variation underlying genetic disease.
Founded in 1995 by Professor Ed Southern, Oxford Gene Technology (OGT) rapidly became one of the leading providers of genetics research solutions. Oxford Gene Technology is a biotech company based in Oxford (UK) and Tarrytown (USA). Oxford Gene Technology’s Board is composed by Edwin Southern, Sonia Morgan, David Owen, Tim Cook, Mike Evans (CEO), Tim Hall, John Anson, James Clough, Martin Lawrie, Tony Lenhardt and Bob Holland. Scientific Advisors are Peter Rigby, Martin Bobrow, Jorge Reis-Filho and Chris Holmes. With customers in more than 60 countries worldwide and ambitious expansion plans, Oxford Gene Technology has a strong reputation and increasing share in the growing genomic medicine market.
More about Oxford Gene Technology: www.ogt.co.uk
Oxford Gene Technology – OGT – SureSeq Solid Tumour Panel – CytoSure Molecular Array – CytoSure Embryo Screen Array – array comparative genomic hybridisation – aCGH – aneuploidy – CytoSure Aneuploidy array – CytoSure Medical Research Exome Array
Oxford Gene Technology – genetic – SureSeq – copy number variations – CNV – microdeletion – microduplication – Cytocell Ltd – FISH probe – CytoSure – Cytocell – SureSeq – Genefficiency – next generation sequencing – NGS – Ed Southern – Edwin Southern – Sonia Morgan – David Owen – Tim Cook – Mike Evans – Tim Hall – John Anson – James Clough – Martin Lawrie – Tony Lenhardt – Bob Holland – Peter Rigby – Martin Bobrow – Jorge Reis-Filho – Chris Holmes